Stopping hemangioma drug abruptly may be as safe as tapering
NCT ID NCT07665177
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether stopping propranolol suddenly or slowly is better for preventing hemangioma regrowth in infants. About 110 children who have taken propranolol for at least 6 months will be randomly assigned to either stop immediately or taper over 4 weeks. The goal is to see which approach leads to fewer cases of rebound growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
propranolol
What this could lead to
If successful, this study could show that abruptly stopping propranolol is as safe as tapering, simplifying treatment for infantile hemangioma.
What could go wrong
This is a phase 4 trial with only 110 participants, so results may not apply to all cases. Rebound growth is still possible with either method.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFANTILE HEMANGIOMA (IH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••